La cadena de opciones muestra datos clave de las opciones de acciones de XORTX Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para XORTX Therapeutics..

XORTX Therapeutics (NASDAQ:XRTX) Bolsa, Cadena de Opciones

XORTX Therapeutics

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

News

Pre-Market Outlook

Markets

ADXN

BYND

CELC

CIIT

DCTH

DGXX

EXEL

FBGL

FCUV

FPAY

NCNA

OLMA

RANI

RAPT

TGHL

VIVK

XRTX

YGMZ

DCTH impulsa el premercado con resultados clínicos positivos del estudio CHOPIN, mientras Beyond Meat y Celcuity lideran las mayores subidas.

Acciones de Delcath Systems (DCTH) suben un 14%; Aquí están 20 acciones que se mueven en el premercado

XORTX Therapeutics Inc

Health Care

Press Releases

XORTX Completes Non-Brokered Private Placement of Units

XORTX Announces USD $114,500 Private Placement

XORTX Provides Corporate Update and Planned Activities for 2025 / 2026

IPOs

XORTX Completes USD $114,500 Private Placement

General

XORTX Initiates IND Preparation for XORLO™ in Gout Program

Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10

XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

Financing

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

TSXV:XRTX

Akanda

Artelo Biosciences

Aspire Biopharma Holdings, Inc. - Warrant

Aspire Biopharma Hldgs

Biofrontera

Clearmind Medicine

CNS Pharma

China Pharma Holding

Enveric Biosciences

Impact BioMedical

InMed Pharmaceuticals Inc. - Common Shares

InMed Pharmaceuticals

Lexaria Bioscience

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

PainReform

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Reviva Pharmaceuticals Holdings, Inc. - Warrants

Reviva Pharmaceuticals

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

SciSparc

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

Alliance Global Partners

Comments

XORTX Therapeutics

XORTX Therapeutics (XRTX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL